WHY? To minimise the impact of asbestos and dust-related diseases worldwide. We are advancing our research into the following key areas:
Dr Ben Johnson’s work on earlier diagnosis of asbestos-related diseases.
Peter Shi’s breakthrough research and how we achieve our mission of improving patient outcomes and uncovering new treatments.
We foster a patient-centric research approach, translating our discoveries into practical solutions. Read about Dr Elham Beheshti’s work here.
“Having a clinical element to ADDRI means that we can be involved in changes that will actually impact not only on the patients now, but the next generation of patients with mesothelioma.” – Dr Anthony Linton, Medical Oncologist, ADDRI Academic and Research Director.